REGN · CIK 0000872589 · operating
Based in Tarrytown, New York, Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines across multiple therapeutic areas including ophthalmology, immunology, oncology, cardiovascular disease, and rare genetic disorders. The company's marketed products include EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. Regeneron maintains partnerships with established pharmaceutical companies and emerging biotechnology firms to expand its pipeline, including collaborations with Bayer on ophthalmic products, Alnylam on RNAi therapeutics, and Intellia on CRISPR-based gene editing.
The company operates across multiple therapeutic areas, with ophthalmology and immunology representing significant revenue sources. Regeneron's business model combines internal research and development capabilities with external partnerships and licensing arrangements to advance candidates in neurology, infectious disease, and metabolic disorders. The company employs approximately 15,400 full-time employees and operates globally, with manufacturing, research, and commercial operations supporting distribution across North America, Europe, and other international markets.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $41.48 | $43.07 | +8.2% | |
| 2024 | $38.34 | $40.90 | +10.3% | |
| 2023 | $34.77 | $37.05 | -9.0% | |
| 2022 | $38.22 | $40.51 | -46.9% | |
| 2021 | $71.97 | $76.40 | +602.8% | |
| 2020 | $10.24 | $10.90 | +47.8% | |
| 2019 | $6.93 | $7.25 | -3.1% | |
| 2018 | $7.15 | $7.58 | +376.7% | |
| 2017 | $1.50 | $1.62 | -31.5% | |
| 2016 | $2.19 | $2.41 | +63.4% | |
| 2015 | $1.34 | $1.49 | +39.6% | |
| 2014 | $0.96 | $1.09 | +11.6% | |
| 2013 | $0.86 | $0.98 | -78.9% | |
| 2012 | $4.08 | $4.92 | — | |
| 2011 | — | — | — | |
| 2010 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-04 | 0000872589-26-000008 | SEC ↗ |
| 2024-12-31 | 2025-02-05 | 0001804220-25-000011 | SEC ↗ |
| 2023-12-31 | 2024-02-05 | 0001804220-24-000009 | SEC ↗ |
| 2022-12-31 | 2023-02-06 | 0001804220-23-000008 | SEC ↗ |
| 2021-12-31 | 2022-02-07 | 0001804220-22-000007 | SEC ↗ |
| 2020-12-31 | 2021-02-08 | 0001804220-21-000008 | SEC ↗ |
| 2019-12-31 | 2020-02-07 | 0001532176-20-000008 | SEC ↗ |
| 2018-12-31 | 2019-02-07 | 0001532176-19-000009 | SEC ↗ |
| 2017-12-31 | 2018-02-08 | 0001532176-18-000013 | SEC ↗ |
| 2016-12-31 | 2017-02-09 | 0001532176-17-000008 | SEC ↗ |